Volume 15, Number 11—November 2009
Research
Epidemic of Plasmodium falciparum Malaria Involving Substandard Antimalarial Drugs, Pakistan, 2003
Toby Leslie
, Harpakash Kaur, Nasir Mohammed, Kate Kolaczinski, Rosalynn L. Ord, and Mark Rowland
, Harpakash Kaur, Nasir Mohammed, Kate Kolaczinski, Rosalynn L. Ord, and Mark Rowland
Table 3
Frequency of treatment failure for infection with Plasmodium falciparum or P. vivax, by group, sex, and age, Pakistan, October 2003*
| Characteristic | Failure rate (%) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|---|
| Group | |||
| Comparison group | 4/40 (10.0) | 1 | 1 |
| Ashgaroo |
43/151 (28.5) |
3.6 (1.2–10.7) |
3.2 (1.0–10.1) |
| Sex | |||
| M | 27/90 (30.0) | 1 | 1 |
| F |
20/99 (20.2)† |
0.6 (0.3–1.2) |
0.5 (0.3–1.2) |
| Age group, y | |||
| 0–5 | 16/40 (40.0) | 1 | 1 |
| 6–10 | 21/72 (29.2) | 0.6 (0.3–1.4) | 0.6 (0.3–1.1) |
| 11–20 | 4/33 (12.2) | 0.2 (0.1–0.7) | 0.3 (0.1–1.0) |
| >20 | 6/46 (13.0) | 0.2 (0.1–0.6) | 0.3 (0.1–0.8) |
*OR, odds ratio; CI, confidence interval.
†Results exclude losses to follow-up.
Page created: December 09, 2010
Page updated: December 09, 2010
Page reviewed: December 09, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.